Many patients notice that nausea, fatigue, or lightheadedness are more pronounced during the first few dose increases
Inspired by Korean Glutathione Shot helps with dark spots and post-breakout marks
Mounjaro (tirzepatide) injection, for subcutaneous use, Food and Drug Administration (2026) FDA approves Lillys Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with Type 2 diabetes, Eli Lilly (2022) Mounjaro (tirzepatide) Injection: The first and only GIP and GLP-1 receptor agonist approved for Type 2 Diabetes, Eli Lilly Declaratory order: Resolution of shortages of tirzepatide injection products (Mounjaro and Zepbound), Food and Drug Administration (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, Food and Drug Administration (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
The FDA has also issued communications regarding unapproved GLP-1 drugs, emphasizing that products containing investigational compounds have not undergone the same review for safety, effectiveness, and quality as approved medications [2]